Keywords: alizyme, colal-pred, ulcerative, colitis, uk, drugmaker, specializing
Alizyme:'s Colal-Pred in ulcerative colitis
Article | 28 March 2005
Alizyme, a UK drugmaker specializing in gastrointestinal disorders, diabetes, and obesity, has received domestic approval for a pivotal Phase III ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
